| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 31 | 2025 | 304 | 8.460 |
Why?
|
| Vascular Surgical Procedures | 24 | 2025 | 532 | 4.570 |
Why?
|
| Lower Extremity | 19 | 2023 | 180 | 3.670 |
Why?
|
| Diabetic Foot | 12 | 2022 | 165 | 3.630 |
Why?
|
| Ischemia | 15 | 2024 | 343 | 3.270 |
Why?
|
| Endovascular Procedures | 21 | 2025 | 752 | 3.240 |
Why?
|
| Intermittent Claudication | 8 | 2025 | 52 | 3.190 |
Why?
|
| Aortic Aneurysm, Abdominal | 11 | 2025 | 370 | 3.020 |
Why?
|
| Liver Transplantation | 30 | 2008 | 1105 | 2.620 |
Why?
|
| Health Care Costs | 6 | 2025 | 392 | 2.440 |
Why?
|
| Blood Vessel Prosthesis Implantation | 16 | 2025 | 734 | 2.390 |
Why?
|
| Osteomyelitis | 5 | 2019 | 207 | 2.250 |
Why?
|
| Gangrene | 5 | 2023 | 27 | 1.920 |
Why?
|
| Watchful Waiting | 2 | 2025 | 73 | 1.770 |
Why?
|
| Leg | 6 | 2022 | 125 | 1.770 |
Why?
|
| Islets of Langerhans Transplantation | 10 | 2006 | 28 | 1.760 |
Why?
|
| Walking | 5 | 2019 | 228 | 1.630 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2021 | 880 | 1.520 |
Why?
|
| Limb Salvage | 13 | 2024 | 141 | 1.520 |
Why?
|
| Foot | 4 | 2023 | 61 | 1.460 |
Why?
|
| Models, Economic | 6 | 2025 | 56 | 1.450 |
Why?
|
| Surgical Wound Infection | 7 | 2020 | 263 | 1.380 |
Why?
|
| Treatment Outcome | 58 | 2025 | 12546 | 1.340 |
Why?
|
| Aortic Rupture | 3 | 2022 | 114 | 1.300 |
Why?
|
| Aged | 56 | 2025 | 20344 | 1.260 |
Why?
|
| Tissue and Organ Procurement | 10 | 2007 | 244 | 1.230 |
Why?
|
| Foot Ulcer | 3 | 2019 | 19 | 1.190 |
Why?
|
| Healthcare Disparities | 4 | 2024 | 482 | 1.190 |
Why?
|
| Risk Factors | 38 | 2025 | 10555 | 1.140 |
Why?
|
| Middle Aged | 65 | 2025 | 27697 | 1.140 |
Why?
|
| Carotid Stenosis | 6 | 2021 | 103 | 1.120 |
Why?
|
| Markov Chains | 8 | 2025 | 94 | 1.100 |
Why?
|
| Time Factors | 38 | 2025 | 6134 | 1.070 |
Why?
|
| Humans | 140 | 2025 | 126753 | 1.050 |
Why?
|
| Exercise Tolerance | 2 | 2018 | 87 | 1.020 |
Why?
|
| Health Behavior | 3 | 2018 | 385 | 0.990 |
Why?
|
| Foot Diseases | 2 | 2017 | 21 | 0.960 |
Why?
|
| Wound Healing | 10 | 2024 | 447 | 0.950 |
Why?
|
| Stents | 10 | 2020 | 769 | 0.940 |
Why?
|
| Male | 85 | 2025 | 62543 | 0.940 |
Why?
|
| Aged, 80 and over | 24 | 2025 | 6668 | 0.920 |
Why?
|
| Life Expectancy | 1 | 2025 | 53 | 0.920 |
Why?
|
| Graft Survival | 13 | 2012 | 454 | 0.900 |
Why?
|
| Cost-Benefit Analysis | 9 | 2025 | 533 | 0.890 |
Why?
|
| Exercise Therapy | 3 | 2025 | 172 | 0.870 |
Why?
|
| Postoperative Complications | 17 | 2025 | 3066 | 0.860 |
Why?
|
| Anemia | 3 | 2025 | 338 | 0.850 |
Why?
|
| Texas | 16 | 2022 | 3551 | 0.840 |
Why?
|
| Retrospective Studies | 48 | 2024 | 17005 | 0.840 |
Why?
|
| Exercise | 3 | 2019 | 839 | 0.820 |
Why?
|
| Medicaid | 2 | 2022 | 241 | 0.810 |
Why?
|
| Female | 77 | 2025 | 68330 | 0.780 |
Why?
|
| Bacteria | 2 | 2019 | 502 | 0.780 |
Why?
|
| Cause of Death | 4 | 2018 | 484 | 0.770 |
Why?
|
| Vascular Diseases | 2 | 2021 | 151 | 0.710 |
Why?
|
| Risk Assessment | 15 | 2025 | 3586 | 0.670 |
Why?
|
| Arterial Occlusive Diseases | 6 | 2019 | 99 | 0.650 |
Why?
|
| Patient Care Bundles | 1 | 2020 | 24 | 0.640 |
Why?
|
| Tibia | 1 | 2020 | 79 | 0.630 |
Why?
|
| Vascular Grafting | 5 | 2019 | 48 | 0.630 |
Why?
|
| Vascular Patency | 10 | 2020 | 178 | 0.630 |
Why?
|
| Delay Discounting | 1 | 2019 | 8 | 0.630 |
Why?
|
| Cost Savings | 2 | 2017 | 78 | 0.630 |
Why?
|
| Treatment Failure | 3 | 2019 | 334 | 0.620 |
Why?
|
| Economics, Behavioral | 1 | 2019 | 8 | 0.620 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 148 | 0.610 |
Why?
|
| Patient Compliance | 2 | 2019 | 458 | 0.610 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2024 | 93 | 0.610 |
Why?
|
| Liver Failure | 5 | 2007 | 89 | 0.600 |
Why?
|
| Veterans Health | 2 | 2019 | 171 | 0.600 |
Why?
|
| Tissue Donors | 6 | 2007 | 491 | 0.590 |
Why?
|
| Waiting Lists | 5 | 2007 | 236 | 0.570 |
Why?
|
| Fenofibrate | 1 | 2018 | 58 | 0.570 |
Why?
|
| Recovery of Function | 3 | 2015 | 439 | 0.560 |
Why?
|
| Health Status Disparities | 1 | 2021 | 258 | 0.560 |
Why?
|
| Health Resources | 1 | 2019 | 127 | 0.560 |
Why?
|
| United States | 20 | 2025 | 11310 | 0.550 |
Why?
|
| Soft Tissue Infections | 1 | 2018 | 88 | 0.540 |
Why?
|
| Veins | 1 | 2018 | 99 | 0.540 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2006 | 217 | 0.540 |
Why?
|
| Severity of Illness Index | 13 | 2024 | 2975 | 0.530 |
Why?
|
| Medical Errors | 3 | 2019 | 152 | 0.530 |
Why?
|
| Fear | 2 | 2017 | 199 | 0.530 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1220 | 0.530 |
Why?
|
| Smoking Cessation | 1 | 2018 | 183 | 0.520 |
Why?
|
| Saphenous Vein | 3 | 2024 | 47 | 0.510 |
Why?
|
| Surgeons | 1 | 2021 | 283 | 0.510 |
Why?
|
| Avoidance Learning | 1 | 2017 | 61 | 0.510 |
Why?
|
| Reoperation | 9 | 2020 | 818 | 0.510 |
Why?
|
| Bone and Bones | 1 | 2019 | 294 | 0.510 |
Why?
|
| Age Factors | 6 | 2025 | 2789 | 0.500 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2016 | 19 | 0.500 |
Why?
|
| Infection Control | 1 | 2018 | 158 | 0.500 |
Why?
|
| Liver Failure, Acute | 3 | 2006 | 91 | 0.490 |
Why?
|
| Staphylococcal Infections | 2 | 2019 | 559 | 0.470 |
Why?
|
| Specialties, Surgical | 2 | 2015 | 89 | 0.460 |
Why?
|
| Blood Vessel Prosthesis | 7 | 2019 | 481 | 0.460 |
Why?
|
| Environment | 1 | 2016 | 146 | 0.450 |
Why?
|
| Amputees | 1 | 2015 | 8 | 0.450 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 873 | 0.450 |
Why?
|
| Multivariate Analysis | 13 | 2017 | 1374 | 0.450 |
Why?
|
| Compartment Syndromes | 1 | 2015 | 32 | 0.450 |
Why?
|
| Mobility Limitation | 1 | 2015 | 32 | 0.450 |
Why?
|
| Self Concept | 1 | 2016 | 155 | 0.440 |
Why?
|
| Patient Selection | 5 | 2014 | 711 | 0.440 |
Why?
|
| Hospitalization | 2 | 2021 | 1874 | 0.440 |
Why?
|
| Hospital Costs | 2 | 2014 | 177 | 0.440 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2006 | 824 | 0.430 |
Why?
|
| Pain | 1 | 2017 | 427 | 0.430 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2024 | 1048 | 0.430 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2016 | 231 | 0.430 |
Why?
|
| Follow-Up Studies | 13 | 2017 | 5114 | 0.430 |
Why?
|
| Renal Dialysis | 4 | 2024 | 932 | 0.420 |
Why?
|
| Social Behavior | 1 | 2016 | 216 | 0.420 |
Why?
|
| Myocardial Infarction | 4 | 2025 | 980 | 0.420 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 658 | 0.420 |
Why?
|
| Databases as Topic | 2 | 2011 | 74 | 0.410 |
Why?
|
| Proportional Hazards Models | 8 | 2018 | 1364 | 0.410 |
Why?
|
| Wound Closure Techniques | 1 | 2013 | 27 | 0.410 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2025 | 123 | 0.410 |
Why?
|
| Kidney Failure, Chronic | 4 | 2024 | 923 | 0.410 |
Why?
|
| Survival Analysis | 8 | 2017 | 1495 | 0.400 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2013 | 74 | 0.400 |
Why?
|
| Survival Rate | 9 | 2019 | 2101 | 0.390 |
Why?
|
| Health Status | 3 | 2016 | 380 | 0.390 |
Why?
|
| Chi-Square Distribution | 6 | 2018 | 557 | 0.390 |
Why?
|
| Health Care Rationing | 3 | 2007 | 59 | 0.380 |
Why?
|
| Acute Kidney Injury | 2 | 2017 | 664 | 0.380 |
Why?
|
| Popliteal Artery | 1 | 2012 | 34 | 0.370 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 200 | 0.360 |
Why?
|
| Wound Infection | 2 | 2024 | 48 | 0.360 |
Why?
|
| Odds Ratio | 9 | 2018 | 1207 | 0.360 |
Why?
|
| Adult | 27 | 2024 | 30410 | 0.360 |
Why?
|
| Cohort Studies | 9 | 2020 | 4954 | 0.350 |
Why?
|
| Anti-Bacterial Agents | 4 | 2019 | 2507 | 0.340 |
Why?
|
| Femoral Artery | 3 | 2020 | 141 | 0.340 |
Why?
|
| Iliac Artery | 3 | 2019 | 64 | 0.340 |
Why?
|
| Hospitals | 3 | 2022 | 428 | 0.330 |
Why?
|
| Palliative Care | 1 | 2014 | 441 | 0.330 |
Why?
|
| Surgical Procedures, Operative | 2 | 2025 | 226 | 0.330 |
Why?
|
| Biliary Atresia | 4 | 2006 | 217 | 0.330 |
Why?
|
| Societies, Medical | 3 | 2021 | 741 | 0.320 |
Why?
|
| Aneurysm, False | 2 | 2008 | 84 | 0.320 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 2015 | 684 | 0.310 |
Why?
|
| Prevalence | 4 | 2017 | 2591 | 0.310 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2019 | 77 | 0.310 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 152 | 0.310 |
Why?
|
| Cation Transport Proteins | 2 | 2007 | 99 | 0.300 |
Why?
|
| Demography | 2 | 2007 | 237 | 0.300 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 202 | 0.300 |
Why?
|
| Blood Transfusion | 3 | 2022 | 287 | 0.300 |
Why?
|
| Immunosuppressive Agents | 5 | 2006 | 649 | 0.290 |
Why?
|
| Leadership | 1 | 2011 | 235 | 0.290 |
Why?
|
| Quality Indicators, Health Care | 1 | 2010 | 227 | 0.280 |
Why?
|
| Veterans | 3 | 2019 | 1741 | 0.280 |
Why?
|
| General Surgery | 2 | 2015 | 219 | 0.280 |
Why?
|
| Angioplasty, Balloon | 3 | 2016 | 129 | 0.270 |
Why?
|
| Advisory Committees | 3 | 2017 | 145 | 0.270 |
Why?
|
| Angiography, Digital Subtraction | 3 | 2016 | 45 | 0.270 |
Why?
|
| Endarterectomy, Carotid | 3 | 2015 | 76 | 0.270 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2007 | 15 | 0.270 |
Why?
|
| Thoracic Neoplasms | 1 | 2007 | 38 | 0.270 |
Why?
|
| Incidence | 7 | 2019 | 3251 | 0.270 |
Why?
|
| Islets of Langerhans | 2 | 2005 | 146 | 0.270 |
Why?
|
| Regional Blood Flow | 2 | 2020 | 190 | 0.270 |
Why?
|
| Decision Support Techniques | 2 | 2025 | 292 | 0.260 |
Why?
|
| Propionates | 1 | 2006 | 33 | 0.260 |
Why?
|
| Liver Diseases | 3 | 2007 | 381 | 0.250 |
Why?
|
| Policy Making | 1 | 2007 | 59 | 0.250 |
Why?
|
| American Heart Association | 3 | 2017 | 307 | 0.250 |
Why?
|
| Graft Rejection | 5 | 2012 | 553 | 0.250 |
Why?
|
| Patient Care Team | 1 | 2011 | 550 | 0.250 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2015 | 2039 | 0.250 |
Why?
|
| Length of Stay | 6 | 2018 | 1377 | 0.250 |
Why?
|
| Predictive Value of Tests | 8 | 2024 | 2225 | 0.250 |
Why?
|
| Sex Factors | 2 | 2021 | 1309 | 0.250 |
Why?
|
| Ankle Brachial Index | 2 | 2016 | 40 | 0.250 |
Why?
|
| Chronic Disease | 5 | 2024 | 1194 | 0.250 |
Why?
|
| Hepatitis C | 2 | 2006 | 380 | 0.240 |
Why?
|
| Prognosis | 7 | 2018 | 4772 | 0.230 |
Why?
|
| Heart Failure | 1 | 2018 | 2289 | 0.230 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2006 | 113 | 0.230 |
Why?
|
| Aneurysm | 2 | 2017 | 70 | 0.230 |
Why?
|
| Quality of Life | 4 | 2016 | 2029 | 0.230 |
Why?
|
| Registries | 5 | 2018 | 1536 | 0.230 |
Why?
|
| Arachnoid | 1 | 2005 | 9 | 0.230 |
Why?
|
| Subarachnoid Space | 1 | 2005 | 24 | 0.230 |
Why?
|
| Growth Disorders | 1 | 2006 | 183 | 0.230 |
Why?
|
| Aortic Aneurysm | 3 | 2014 | 221 | 0.220 |
Why?
|
| Attitude | 1 | 2005 | 108 | 0.220 |
Why?
|
| Logistic Models | 8 | 2018 | 1779 | 0.220 |
Why?
|
| Parenteral Nutrition | 1 | 2006 | 214 | 0.220 |
Why?
|
| Iatrogenic Disease | 2 | 2013 | 120 | 0.220 |
Why?
|
| West Nile Fever | 1 | 2006 | 137 | 0.220 |
Why?
|
| Interleukin-1 | 1 | 2005 | 131 | 0.220 |
Why?
|
| Forearm | 1 | 2024 | 38 | 0.220 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 168 | 0.220 |
Why?
|
| Disease Management | 3 | 2017 | 541 | 0.220 |
Why?
|
| Cerebrospinal Fluid | 1 | 2005 | 95 | 0.220 |
Why?
|
| Alanine Transaminase | 1 | 2005 | 154 | 0.220 |
Why?
|
| Hepacivirus | 1 | 2006 | 263 | 0.220 |
Why?
|
| Erythrocyte Transfusion | 1 | 2025 | 136 | 0.220 |
Why?
|
| Hepatic Veins | 1 | 2004 | 20 | 0.220 |
Why?
|
| Carotid Artery, Common | 2 | 2015 | 59 | 0.210 |
Why?
|
| Angioplasty | 3 | 2013 | 66 | 0.210 |
Why?
|
| Ileal Diseases | 1 | 2004 | 27 | 0.210 |
Why?
|
| Antimetabolites | 1 | 2004 | 28 | 0.210 |
Why?
|
| Calcineurin Inhibitors | 1 | 2004 | 20 | 0.210 |
Why?
|
| Ganciclovir | 1 | 2004 | 100 | 0.210 |
Why?
|
| Postoperative Care | 1 | 2025 | 306 | 0.200 |
Why?
|
| Heptanoic Acids | 1 | 2003 | 77 | 0.200 |
Why?
|
| Fibrinolytic Agents | 1 | 2025 | 198 | 0.200 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2006 | 273 | 0.200 |
Why?
|
| Intussusception | 1 | 2004 | 54 | 0.200 |
Why?
|
| Cytomegalovirus | 2 | 2005 | 257 | 0.200 |
Why?
|
| Massachusetts | 2 | 2015 | 116 | 0.200 |
Why?
|
| Groin | 2 | 2013 | 14 | 0.200 |
Why?
|
| Career Choice | 1 | 2004 | 158 | 0.200 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2015 | 228 | 0.200 |
Why?
|
| Diabetic Neuropathies | 3 | 2017 | 55 | 0.200 |
Why?
|
| Critical Illness | 4 | 2018 | 604 | 0.190 |
Why?
|
| Health Surveys | 2 | 2018 | 248 | 0.190 |
Why?
|
| Cost of Illness | 2 | 2017 | 283 | 0.190 |
Why?
|
| Prosthesis-Related Infections | 2 | 2016 | 183 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 572 | 0.190 |
Why?
|
| Pyrroles | 1 | 2003 | 184 | 0.190 |
Why?
|
| Computer Simulation | 2 | 2016 | 665 | 0.180 |
Why?
|
| Sirolimus | 1 | 2003 | 222 | 0.180 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2015 | 379 | 0.180 |
Why?
|
| Prospective Studies | 10 | 2024 | 6214 | 0.180 |
Why?
|
| Surveys and Questionnaires | 4 | 2017 | 3907 | 0.180 |
Why?
|
| Comorbidity | 5 | 2014 | 1559 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2004 | 217 | 0.180 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2004 | 320 | 0.180 |
Why?
|
| Transplantation, Homologous | 4 | 2007 | 639 | 0.180 |
Why?
|
| Cardiology | 2 | 2016 | 487 | 0.180 |
Why?
|
| Lung Transplantation | 1 | 2005 | 344 | 0.170 |
Why?
|
| Hemoglobins | 3 | 2025 | 311 | 0.170 |
Why?
|
| Adolescent | 13 | 2019 | 20002 | 0.170 |
Why?
|
| Culturally Competent Care | 1 | 2021 | 49 | 0.170 |
Why?
|
| Recurrence | 4 | 2019 | 1406 | 0.170 |
Why?
|
| Child, Preschool | 12 | 2008 | 14347 | 0.170 |
Why?
|
| Liver | 5 | 2008 | 1765 | 0.160 |
Why?
|
| Reproducibility of Results | 4 | 2016 | 2883 | 0.160 |
Why?
|
| Glomerular Filtration Rate | 2 | 2014 | 539 | 0.160 |
Why?
|
| Graft vs Host Disease | 1 | 2005 | 631 | 0.160 |
Why?
|
| Students, Medical | 1 | 2004 | 337 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2025 | 1259 | 0.160 |
Why?
|
| Algorithms | 2 | 2006 | 1633 | 0.160 |
Why?
|
| Heart Transplantation | 1 | 2007 | 866 | 0.160 |
Why?
|
| Spatial Analysis | 1 | 2019 | 28 | 0.160 |
Why?
|
| Venous Thrombosis | 2 | 2014 | 168 | 0.160 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 46 | 0.160 |
Why?
|
| History, 20th Century | 2 | 2015 | 369 | 0.160 |
Why?
|
| Transportation | 1 | 2019 | 27 | 0.160 |
Why?
|
| Hospitals, Low-Volume | 1 | 2019 | 32 | 0.160 |
Why?
|
| Geography | 1 | 2019 | 118 | 0.160 |
Why?
|
| Hospitals, High-Volume | 1 | 2019 | 40 | 0.150 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 42 | 0.150 |
Why?
|
| Medicare | 1 | 2022 | 424 | 0.150 |
Why?
|
| Aortography | 3 | 2015 | 159 | 0.150 |
Why?
|
| Cadaver | 4 | 2007 | 116 | 0.150 |
Why?
|
| Operating Rooms | 1 | 2019 | 75 | 0.150 |
Why?
|
| Disease Progression | 4 | 2016 | 2109 | 0.150 |
Why?
|
| Operative Time | 3 | 2019 | 193 | 0.150 |
Why?
|
| Enterococcus | 1 | 2019 | 31 | 0.150 |
Why?
|
| Healthy Lifestyle | 1 | 2018 | 32 | 0.150 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 898 | 0.140 |
Why?
|
| Arteries | 1 | 2019 | 194 | 0.140 |
Why?
|
| Apoptosis | 1 | 2005 | 1811 | 0.140 |
Why?
|
| Catheters, Indwelling | 1 | 2019 | 150 | 0.140 |
Why?
|
| Diabetic Angiopathies | 2 | 2017 | 66 | 0.140 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 452 | 0.140 |
Why?
|
| Propensity Score | 3 | 2020 | 250 | 0.140 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 247 | 0.140 |
Why?
|
| Patient Readmission | 3 | 2020 | 413 | 0.130 |
Why?
|
| Evidence-Based Medicine | 3 | 2025 | 613 | 0.130 |
Why?
|
| Reperfusion Injury | 2 | 2008 | 108 | 0.130 |
Why?
|
| Ultrasonography, Doppler, Duplex | 2 | 2015 | 33 | 0.130 |
Why?
|
| Serum Albumin | 1 | 2017 | 110 | 0.130 |
Why?
|
| Prosthesis Design | 5 | 2020 | 613 | 0.130 |
Why?
|
| Angiography | 2 | 2015 | 192 | 0.130 |
Why?
|
| Blood Gas Monitoring, Transcutaneous | 1 | 2016 | 4 | 0.130 |
Why?
|
| Radiography | 5 | 2013 | 752 | 0.130 |
Why?
|
| Biopsy | 2 | 2019 | 1236 | 0.130 |
Why?
|
| Databases, Factual | 3 | 2006 | 1193 | 0.130 |
Why?
|
| Child | 12 | 2008 | 25101 | 0.120 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 154 | 0.120 |
Why?
|
| Equipment Design | 2 | 2015 | 575 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2017 | 1398 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2016 | 799 | 0.120 |
Why?
|
| Hepatocytes | 3 | 2007 | 231 | 0.120 |
Why?
|
| Learning Curve | 2 | 2012 | 55 | 0.120 |
Why?
|
| Low Back Pain | 1 | 2016 | 39 | 0.120 |
Why?
|
| Immunity, Cellular | 2 | 2006 | 196 | 0.120 |
Why?
|
| Self Report | 1 | 2018 | 534 | 0.120 |
Why?
|
| Pancreas Transplantation | 2 | 2006 | 30 | 0.120 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 470 | 0.110 |
Why?
|
| Fasciotomy | 1 | 2015 | 24 | 0.110 |
Why?
|
| Artificial Limbs | 1 | 2015 | 7 | 0.110 |
Why?
|
| Age Distribution | 2 | 2006 | 422 | 0.110 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 128 | 0.110 |
Why?
|
| History, 18th Century | 1 | 2015 | 69 | 0.110 |
Why?
|
| Polyethylenes | 1 | 2014 | 7 | 0.110 |
Why?
|
| Acute Disease | 2 | 2015 | 1135 | 0.110 |
Why?
|
| Silver Compounds | 1 | 2014 | 7 | 0.110 |
Why?
|
| Infant | 9 | 2007 | 12771 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 3 | 2006 | 613 | 0.110 |
Why?
|
| History, 19th Century | 1 | 2015 | 110 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 393 | 0.110 |
Why?
|
| Alginates | 1 | 2014 | 23 | 0.110 |
Why?
|
| Decompression, Surgical | 1 | 2015 | 82 | 0.110 |
Why?
|
| Patient Safety | 1 | 2019 | 434 | 0.110 |
Why?
|
| Polyesters | 1 | 2014 | 34 | 0.110 |
Why?
|
| Vena Cava Filters | 1 | 2014 | 19 | 0.110 |
Why?
|
| Prosthesis Fitting | 1 | 2014 | 11 | 0.110 |
Why?
|
| Heart Diseases | 2 | 2017 | 490 | 0.110 |
Why?
|
| Osteoarthritis | 1 | 2016 | 97 | 0.110 |
Why?
|
| Chemistry, Clinical | 1 | 2014 | 11 | 0.110 |
Why?
|
| Foreign-Body Migration | 1 | 2014 | 57 | 0.110 |
Why?
|
| Vancomycin | 2 | 2013 | 221 | 0.110 |
Why?
|
| Bandages | 1 | 2014 | 54 | 0.110 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2014 | 39 | 0.110 |
Why?
|
| Renal Artery Obstruction | 1 | 2014 | 40 | 0.110 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2014 | 66 | 0.110 |
Why?
|
| Carotid Artery Injuries | 1 | 2013 | 35 | 0.100 |
Why?
|
| Skin Transplantation | 1 | 2013 | 57 | 0.100 |
Why?
|
| Vascular Access Devices | 1 | 2013 | 35 | 0.100 |
Why?
|
| Consensus | 3 | 2025 | 555 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 684 | 0.100 |
Why?
|
| Polymethyl Methacrylate | 1 | 2012 | 13 | 0.100 |
Why?
|
| Emergencies | 1 | 2014 | 179 | 0.100 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2017 | 692 | 0.100 |
Why?
|
| Amputation Stumps | 1 | 2012 | 1 | 0.100 |
Why?
|
| Coronary Stenosis | 1 | 2013 | 78 | 0.100 |
Why?
|
| Polytetrafluoroethylene | 1 | 2013 | 63 | 0.100 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2013 | 49 | 0.100 |
Why?
|
| Kidney | 3 | 2016 | 1283 | 0.100 |
Why?
|
| Mental Health | 1 | 2016 | 363 | 0.090 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2012 | 73 | 0.090 |
Why?
|
| Aortic Diseases | 1 | 2014 | 186 | 0.090 |
Why?
|
| Postoperative Hemorrhage | 1 | 2013 | 81 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2012 | 115 | 0.090 |
Why?
|
| Catheterization, Central Venous | 1 | 2013 | 140 | 0.090 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2012 | 87 | 0.090 |
Why?
|
| Device Removal | 1 | 2013 | 220 | 0.090 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 119 | 0.090 |
Why?
|
| Surgical Flaps | 1 | 2013 | 185 | 0.090 |
Why?
|
| Balloon Occlusion | 1 | 2011 | 48 | 0.090 |
Why?
|
| Anastomosis, Surgical | 1 | 2012 | 165 | 0.090 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 249 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2015 | 542 | 0.090 |
Why?
|
| Research Design | 3 | 2010 | 691 | 0.090 |
Why?
|
| Bile | 2 | 2008 | 44 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 815 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 424 | 0.090 |
Why?
|
| Contrast Media | 1 | 2014 | 459 | 0.080 |
Why?
|
| Database Management Systems | 1 | 2010 | 27 | 0.080 |
Why?
|
| DNA, Viral | 3 | 2006 | 448 | 0.080 |
Why?
|
| Models, Statistical | 2 | 2019 | 466 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3662 | 0.080 |
Why?
|
| Catheterization, Peripheral | 1 | 2012 | 128 | 0.080 |
Why?
|
| Intention to Treat Analysis | 2 | 2024 | 61 | 0.080 |
Why?
|
| Anesthesia | 1 | 2012 | 208 | 0.080 |
Why?
|
| Viral Load | 3 | 2006 | 398 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 217 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 2 | 2008 | 80 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2006 | 358 | 0.070 |
Why?
|
| Biomarkers | 4 | 2017 | 3222 | 0.070 |
Why?
|
| Body Height | 2 | 2007 | 191 | 0.070 |
Why?
|
| Cold Ischemia | 1 | 2008 | 28 | 0.070 |
Why?
|
| P-Selectin | 1 | 2008 | 68 | 0.070 |
Why?
|
| Laminectomy | 1 | 2008 | 23 | 0.070 |
Why?
|
| Phlebography | 1 | 2008 | 42 | 0.070 |
Why?
|
| Transplants | 1 | 2008 | 36 | 0.070 |
Why?
|
| Perfusion | 2 | 2008 | 207 | 0.070 |
Why?
|
| Surgical Stapling | 1 | 2008 | 17 | 0.070 |
Why?
|
| Bile Canaliculi | 1 | 2007 | 4 | 0.070 |
Why?
|
| Young Adult | 2 | 2019 | 9665 | 0.070 |
Why?
|
| Anticoagulants | 2 | 2014 | 581 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 2008 | 103 | 0.070 |
Why?
|
| Bradycardia | 1 | 2007 | 55 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 351 | 0.070 |
Why?
|
| Diabetic Retinopathy | 2 | 2006 | 83 | 0.070 |
Why?
|
| Thrombectomy | 1 | 2008 | 105 | 0.070 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2007 | 104 | 0.070 |
Why?
|
| Likelihood Functions | 1 | 2007 | 113 | 0.070 |
Why?
|
| Risk Adjustment | 1 | 2007 | 54 | 0.060 |
Why?
|
| Eligibility Determination | 1 | 2007 | 36 | 0.060 |
Why?
|
| Depression | 1 | 2016 | 1293 | 0.060 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2007 | 35 | 0.060 |
Why?
|
| Adenosine Triphosphatases | 1 | 2007 | 186 | 0.060 |
Why?
|
| Resource Allocation | 1 | 2007 | 52 | 0.060 |
Why?
|
| Government Regulation | 1 | 2007 | 43 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2008 | 171 | 0.060 |
Why?
|
| Hemangioendothelioma | 1 | 2006 | 24 | 0.060 |
Why?
|
| Plasma Cells | 1 | 2007 | 53 | 0.060 |
Why?
|
| CD3 Complex | 1 | 2006 | 91 | 0.060 |
Why?
|
| Hyperplasia | 1 | 2007 | 184 | 0.060 |
Why?
|
| Epoprostenol | 1 | 2006 | 42 | 0.060 |
Why?
|
| Social Justice | 1 | 2007 | 65 | 0.060 |
Why?
|
| Thrombolytic Therapy | 1 | 2008 | 205 | 0.060 |
Why?
|
| Cholangiocarcinoma | 1 | 2007 | 124 | 0.060 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2007 | 192 | 0.060 |
Why?
|
| Bile Duct Neoplasms | 1 | 2007 | 125 | 0.060 |
Why?
|
| Elective Surgical Procedures | 2 | 2017 | 152 | 0.060 |
Why?
|
| Cross Circulation | 1 | 2005 | 3 | 0.060 |
Why?
|
| Hypotension | 1 | 2007 | 182 | 0.060 |
Why?
|
| Hemoperfusion | 1 | 2005 | 4 | 0.060 |
Why?
|
| 3' Untranslated Regions | 1 | 2006 | 154 | 0.060 |
Why?
|
| Liver, Artificial | 1 | 2005 | 8 | 0.060 |
Why?
|
| Dialysis | 1 | 2005 | 18 | 0.060 |
Why?
|
| Life Support Care | 1 | 2006 | 48 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2007 | 264 | 0.060 |
Why?
|
| Anthropometry | 1 | 2006 | 190 | 0.060 |
Why?
|
| Hypothyroidism | 1 | 2006 | 78 | 0.060 |
Why?
|
| Hemodiafiltration | 1 | 2005 | 16 | 0.060 |
Why?
|
| Probability | 1 | 2006 | 302 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2012 | 1018 | 0.060 |
Why?
|
| Plasmapheresis | 1 | 2005 | 31 | 0.060 |
Why?
|
| Hypertension, Portal | 1 | 2006 | 76 | 0.060 |
Why?
|
| Body Weight | 2 | 2007 | 970 | 0.060 |
Why?
|
| Embolization, Therapeutic | 1 | 2008 | 221 | 0.060 |
Why?
|
| Portal Pressure | 1 | 2005 | 4 | 0.060 |
Why?
|
| Residence Characteristics | 1 | 2007 | 271 | 0.060 |
Why?
|
| Extracorporeal Circulation | 1 | 2005 | 53 | 0.060 |
Why?
|
| Albumins | 1 | 2005 | 89 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2025 | 233 | 0.060 |
Why?
|
| Primates | 1 | 2005 | 79 | 0.060 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2005 | 7 | 0.060 |
Why?
|
| Hemochromatosis | 1 | 2005 | 38 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 2006 | 8347 | 0.060 |
Why?
|
| Ependyma | 1 | 2005 | 7 | 0.060 |
Why?
|
| Gastroschisis | 1 | 2005 | 58 | 0.060 |
Why?
|
| Kupffer Cells | 1 | 2005 | 20 | 0.060 |
Why?
|
| Choroid Plexus | 1 | 2005 | 24 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 66 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2005 | 56 | 0.060 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 251 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2006 | 194 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2006 | 354 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2005 | 89 | 0.060 |
Why?
|
| Iron | 1 | 2007 | 298 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2007 | 358 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 126 | 0.050 |
Why?
|
| Hepatectomy | 1 | 2005 | 119 | 0.050 |
Why?
|
| Cerebral Ventricles | 1 | 2005 | 80 | 0.050 |
Why?
|
| Portal Vein | 1 | 2005 | 88 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2012 | 1654 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2006 | 950 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2006 | 299 | 0.050 |
Why?
|
| Survivors | 1 | 2007 | 345 | 0.050 |
Why?
|
| Arm | 1 | 2024 | 72 | 0.050 |
Why?
|
| Florida | 1 | 2004 | 71 | 0.050 |
Why?
|
| Malnutrition | 1 | 2006 | 150 | 0.050 |
Why?
|
| Muromonab-CD3 | 1 | 2004 | 7 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2004 | 59 | 0.050 |
Why?
|
| Fatigue | 1 | 2005 | 195 | 0.050 |
Why?
|
| Creatinine | 1 | 2006 | 381 | 0.050 |
Why?
|
| Propylene Glycols | 1 | 2004 | 19 | 0.050 |
Why?
|
| Sphingosine | 1 | 2004 | 20 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2005 | 221 | 0.050 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2004 | 33 | 0.050 |
Why?
|
| Hypoglycemia | 1 | 2005 | 176 | 0.050 |
Why?
|
| Administration, Topical | 2 | 2014 | 110 | 0.050 |
Why?
|
| Animals | 6 | 2008 | 33051 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2005 | 248 | 0.050 |
Why?
|
| Insulin | 2 | 2008 | 1128 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 399 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2004 | 126 | 0.050 |
Why?
|
| Pancreas | 1 | 2004 | 215 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 785 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2003 | 240 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 1184 | 0.050 |
Why?
|
| Rituximab | 1 | 2004 | 166 | 0.050 |
Why?
|
| ROC Curve | 2 | 2015 | 587 | 0.050 |
Why?
|
| Emotions | 1 | 2005 | 356 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2005 | 824 | 0.050 |
Why?
|
| Suture Techniques | 2 | 2013 | 169 | 0.050 |
Why?
|
| Swine | 1 | 2005 | 1171 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2005 | 461 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 622 | 0.040 |
Why?
|
| Hypertension, Pulmonary | 1 | 2006 | 452 | 0.040 |
Why?
|
| Constriction, Pathologic | 2 | 2012 | 227 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2005 | 1428 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2025 | 1047 | 0.040 |
Why?
|
| Linear Models | 2 | 2012 | 681 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2005 | 1082 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 560 | 0.040 |
Why?
|
| Metatarsus | 1 | 2020 | 2 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 72 | 0.040 |
Why?
|
| Knee | 1 | 2020 | 19 | 0.040 |
Why?
|
| Metals | 1 | 2020 | 56 | 0.040 |
Why?
|
| Cytokines | 1 | 2006 | 1320 | 0.040 |
Why?
|
| Drug-Eluting Stents | 1 | 2020 | 63 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 2065 | 0.040 |
Why?
|
| Anxiety | 1 | 2005 | 964 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2004 | 740 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 759 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 988 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2019 | 193 | 0.030 |
Why?
|
| Inflammation | 1 | 2005 | 1420 | 0.030 |
Why?
|
| Burnout, Professional | 1 | 2019 | 128 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 1493 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2005 | 1569 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 79 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2003 | 734 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 86 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 1351 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1584 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2008 | 1126 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 3262 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 209 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 2014 | 6 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 2014 | 14 | 0.030 |
Why?
|
| Boston | 1 | 2014 | 112 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2017 | 285 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 489 | 0.030 |
Why?
|
| Citric Acid | 1 | 2014 | 40 | 0.030 |
Why?
|
| Blood Specimen Collection | 1 | 2014 | 45 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 497 | 0.030 |
Why?
|
| Forecasting | 1 | 2015 | 355 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2015 | 429 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 240 | 0.030 |
Why?
|
| Jugular Veins | 1 | 2013 | 73 | 0.030 |
Why?
|
| Tobramycin | 1 | 2012 | 19 | 0.020 |
Why?
|
| Patient Transfer | 1 | 2014 | 107 | 0.020 |
Why?
|
| Powders | 1 | 2013 | 26 | 0.020 |
Why?
|
| Antisepsis | 1 | 2012 | 7 | 0.020 |
Why?
|
| Respiration Disorders | 1 | 2013 | 32 | 0.020 |
Why?
|
| Transfusion Reaction | 1 | 2013 | 41 | 0.020 |
Why?
|
| Therapeutic Irrigation | 1 | 2013 | 42 | 0.020 |
Why?
|
| Anesthesia Recovery Period | 1 | 2012 | 22 | 0.020 |
Why?
|
| Disarticulation | 1 | 2012 | 1 | 0.020 |
Why?
|
| Heparin | 1 | 2014 | 206 | 0.020 |
Why?
|
| Gentamicins | 1 | 2012 | 83 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3314 | 0.020 |
Why?
|
| Hip Joint | 1 | 2012 | 50 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2013 | 123 | 0.020 |
Why?
|
| Rats | 2 | 2008 | 3390 | 0.020 |
Why?
|
| Catheters | 1 | 2012 | 82 | 0.020 |
Why?
|
| Morbidity | 1 | 2012 | 245 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 951 | 0.020 |
Why?
|
| Blood Pressure | 2 | 2008 | 1312 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 84 | 0.020 |
Why?
|
| Antiviral Agents | 2 | 2006 | 757 | 0.020 |
Why?
|
| Cognition | 1 | 2015 | 784 | 0.020 |
Why?
|
| Acute Coronary Syndrome | 1 | 2013 | 239 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 1137 | 0.020 |
Why?
|
| Raffinose | 1 | 2008 | 6 | 0.020 |
Why?
|
| Glutathione Disulfide | 1 | 2008 | 20 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2013 | 495 | 0.020 |
Why?
|
| Organ Preservation Solutions | 1 | 2008 | 18 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 116 | 0.020 |
Why?
|
| Necrosis | 1 | 2008 | 190 | 0.020 |
Why?
|
| Stroke | 1 | 2016 | 1027 | 0.020 |
Why?
|
| Polyvinyl Alcohol | 1 | 2008 | 13 | 0.020 |
Why?
|
| Platinum | 1 | 2008 | 13 | 0.020 |
Why?
|
| Splenic Artery | 1 | 2008 | 21 | 0.020 |
Why?
|
| Aspartate Aminotransferase, Mitochondrial | 1 | 2007 | 1 | 0.020 |
Why?
|
| Ceruloplasmin | 1 | 2007 | 13 | 0.020 |
Why?
|
| Adenosine | 1 | 2008 | 126 | 0.020 |
Why?
|
| Allopurinol | 1 | 2008 | 77 | 0.020 |
Why?
|
| Copper-transporting ATPases | 1 | 2007 | 23 | 0.020 |
Why?
|
| Renal Artery | 1 | 2008 | 67 | 0.020 |
Why?
|
| Trace Elements | 1 | 2007 | 21 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2008 | 115 | 0.020 |
Why?
|
| Splenectomy | 1 | 2008 | 62 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2008 | 120 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2008 | 822 | 0.020 |
Why?
|
| Glutathione | 1 | 2008 | 195 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2008 | 169 | 0.020 |
Why?
|
| Biological Transport | 1 | 2007 | 327 | 0.020 |
Why?
|
| Palatine Tonsil | 1 | 2007 | 35 | 0.020 |
Why?
|
| Neutrophils | 1 | 2008 | 349 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2008 | 438 | 0.020 |
Why?
|
| Living Donors | 1 | 2007 | 115 | 0.020 |
Why?
|
| Remission Induction | 1 | 2006 | 298 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2006 | 266 | 0.010 |
Why?
|
| Abdominal Pain | 1 | 2008 | 308 | 0.010 |
Why?
|
| Salivary Glands, Minor | 1 | 2005 | 9 | 0.010 |
Why?
|
| Actins | 1 | 2007 | 311 | 0.010 |
Why?
|
| Hypertension | 1 | 2014 | 1301 | 0.010 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2007 | 119 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 2006 | 113 | 0.010 |
Why?
|
| C-Peptide | 1 | 2005 | 93 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2005 | 156 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 536 | 0.010 |
Why?
|
| Endoscopy | 1 | 2007 | 280 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2005 | 193 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 336 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2005 | 148 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 2006 | 236 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2006 | 249 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2006 | 354 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 792 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 2537 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 1222 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 1479 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 4429 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 3695 | 0.010 |
Why?
|